Navigation Links
PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research

PRINCETON, N.J., Aug. 30 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that Anthony Maida, PhD has joined the Company as Vice President, Clinical Research. Dr. Maida will be responsible for leading PharmaNet's oncology team.

"Anthony's experience spans the drug development process. He has a unique strength in his well balanced expertise across strategic, operational and financial aspects of the business," said Dr. Robert Reekie, Chief Operating Officer and Senior Executive Vice President, Late Stage Development. "We are pleased to have Anthony as part of our outstanding oncology team."

Dr. Maida has more than twenty years of experience providing strategic, operational, and financial expertise to pharmaceutical companies that are focused primarily in the area of oncology.  Most recently, he ran his own consulting firm providing both pharmaceutical product development and capital raising capabilities to pharmaceutical firms, working with venture capital funds and investment banks. Prior to joining the pharmaceutical industry, Dr. Maida worked for Lockheed Corporation in a number of key financial roles.

Dr. Maida earned Bachelor of Arts degrees from the University of Santa Clara and San Jose State University, a Masters of Business Administration degree from the University of Santa Clara, a Masters degree in Toxicology from San Jose State University and a PhD in Tumor Immunology, from the University of California, Davis.  

About PharmaNet Development Group, Inc. PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at  Contact: Anne-Marie HessPhone: (609) 951-6842E-mail:

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
2. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
3. Christopher Brennan Joins PharmaNet Development Group as General Counsel
4. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
5. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
6. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
7. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
8. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
11. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... prospective initiatives designed to create shareholder value. ... of Spherix. "Based on published reports, the total ... $50 billion and Spherix will seek to secure ...
(Date:11/30/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, ... Cypher Genomics, Inc., a leading genome informatics company offering ... solutions. The San Diego -based company ... CEO and Co-founder, Ashley Van Zeeland , Ph.D., who ... details of the deal were not disclosed. ...
(Date:11/30/2015)... ENGLEWOOD, Colo. , Nov. 30, 2015  Aytu ... focused on urological and related conditions, will present at ... live at, an interactive real-time virtual conference, to ... Main Event Investor Conference, to be held December 2 ... Los Angeles and streamed live via ...
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... an additional independent director, and the Company welcomes ... allegations in a recent anonymous internet report on NW ... initiatives. Linda Powers stated, "We agree ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/26/2015)... Calif. , Oct. 26, 2015  Delta ID ... biometric authentication to mobile and PC devices, announced its ... smartphone, the arrows NX F-02H launched by NTT DOCOMO, ... NX F-02H is the second smartphone to include iris ... technology in ARROWS NX F-04G in May 2015, world,s ...
Breaking Biology News(10 mins):